PNH drug safety study ends early: what happened?
Disease control
Terminated
This study aimed to monitor the long-term safety of BCX9930 in people with paroxysmal nocturnal hemoglobinuria (PNH) who had already benefited from the drug in a previous study. It included 28 participants who continued taking BCX9930 because they had no other good treatment opti…
Phase: PHASE2 • Sponsor: BioCryst Pharmaceuticals • Aim: Disease control
Last updated May 13, 2026 16:00 UTC